0001585608 false --12-31 0001585608 2022-03-17 2022-03-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 17, 2022

 

 

 

JAGUAR HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36714 46-2956775
(State or other jurisdiction of
incorporation)
(Commission File Number) (IRS Employer Identification No.)

 

200 Pine Street, Suite 400

San Francisco, California

94104
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (415) 371-8300

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per Share JAGX The NASDAQ Capital Market

 

 

 

   

 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On March 17, 2022, the Board of Directors (the “Board”) of Jaguar Health, Inc. (the “Company”) approved an amendment (the “Bylaws Amendment”) to the Amended and Restated Bylaws of the Company (the “Bylaws”), effective immediately. The Bylaws Amendment amended Section 2.8 of Article II of the Bylaws to reduce the quorum requirements of all meetings of the stockholders of the Company from a majority to the holders of one third (1/3) in voting power of the capital stock issued and outstanding and entitled to vote. The description of the Bylaws Amendment is qualified in its entirety by reference to the First Amendment to the Amended and Restated Bylaws of the Company, as set forth in Exhibit 3.1 to this Report on Form 8-K and incorporated in this item by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  Exhibit

 

Exhibit No.   Description
3.1   First Amendment to the Amended and Restated Bylaws, dated March 17, 2022.
104   Cover Page Interactive Data File (embedded with the inline XBRL document)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  JAGUAR HEALTH, INC.
       
       
  By: /s/ Lisa A. Conte
    Name: Lisa A. Conte
    Title: Chief Executive Officer & President
       
Date: March 18, 2022      
       

 

3

 

Exhibit 3.1

 

First AMENDMENT TO THE

AMENDED AND RESTATED BYLAWS

OF Jaguar Health, INC.

 

THIS FIRST AMENDMENT TO THE AMENDED AND RESTATED BYLAWS of Jaguar Health, Inc., a Delaware corporation (the “Corporation”), is made as of this 17th day of March, 2022.

 

1. Section 2.8 of the Amended and Restated Bylaws is hereby amended and restated in its entirety to read as follows:

 

“2.8 QUORUM.

 

Unless otherwise required by law, the Certificate of Incorporation or these Bylaws, the holders of one third (1/3) in voting power of the capital stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. If, however, a quorum is not present or represented at any meeting of the stockholders, then either (a) the chairperson of the meeting or (b) a majority in voting power of the stockholders entitled to vote thereon, present in person, or by remote communication, if applicable, or represented by proxy, shall have power to adjourn the meeting from time to time in the manner provided in Section 2.9 of these Bylaws until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.”

 

2. Except as specifically amended herein, the Amended and Restated Bylaws shall remain unchanged and in full force and effect.

 

[Remainder of page intentionally left blank]

 

 

 

Jaguar Health, INC.

CERTIFICATE OF ADOPTION OF First Amendment TO

AMENDED AND RESTATED BYLAWS

 

The undersigned hereby certifies that he or she is the duly elected, qualified, and acting Secretary of Jaguar Health, Inc., a Delaware corporation, and that the foregoing First Amendment to the Amended and Restated Bylaws constitutes the entire amendment to the Amended and Restated Bylaws as duly adopted by the Board of Directors by unanimous written consent on March 17th 2022.

 

Executed on March 17, 2022.

 

/s/ Steven R. King
Steven R. King
 Secretary